Auxilium Pharmaceuticals to Present at the 2008 Wachovia Healthcare Conference
MALVERN, PA--(Marketwire - January 25, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
today announced that Mr. Armando Anido, Chief Executive Officer and
President, and Mr. Jim Fickenscher, Chief Financial Officer, will
participate in the 2008 Wachovia Healthcare Conference to be held January
29 through January 31, 2008 at The Langham Hotel in Boston. Mr. Anido is
scheduled to present an overview of the Company and its product pipeline at
1:00 p.m. Eastern Time on Thursday, January 31, 2008.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for thirty days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has four
projects in clinical development. XIAFLEX™ (clostridial collagenase for
injection), formerly referred to as AA4500, is in phase III of development
for the treatment of Dupuytren's contracture and is in phase II of
development for the treatment of Peyronie's disease and Frozen Shoulder
syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product
candidate for the treatment of overactive bladder (AA4010) is in phase I of
development. The Company is currently seeking a partner to further develop
this product candidate. Auxilium has two pain products using its
transmucosal film delivery system in pre-clinical development. Auxilium has
rights to six additional pain products and products for hormone replacement
and urologic disease using its transmucosal film delivery system. Auxilium
also has options to all indications using XIAFLEX for non-topical
formulations. For additional information, visit http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the 2008 Wachovia
Healthcare Conference, and the Company's products in development for
Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome,
overactive bladder, pain, hormone replacement and urologic disease. All
statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries and those discussed in the
Company's Annual Report on Form 10-K for the year ended December 31, 2006
and in the Company's Quarterly Report on Form 10-Q for the period ended
September 30, 2007 under the heading "Risk Factors", which are on file with
the Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of the Company's home page on the Internet
at http://www.auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that the Company does not presently
know or that the Company currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.
Contact Information: Auxilium Pharmaceuticals, Inc.
James E. Fickenscher
CFO
(484) 321-5900
Lazar Partners, Ltd.
Fern Lazar
(212) 867-1765